A pooled subanalysis of the efficacy of certolizumab pegol in patients with self-reported psoriatic arthritis in ongoing phase 3 psoriasis studies (CIMPASI-1, CIMPASI-2, and CIMPACT) - 03/08/18
Alice B. Gottlieb, New York Medical College; Joseph F. Merola, Brigham and Women’s Hospital and Harvard Medical School; Kristian Reich, SCIderm Research Institute and Dermatologikum Hamburg; Diamant Thaçi, University of Lubeck; Laura Coates, University of Leeds; Janice Drew, Dermira, Inc.; Daniel Burge, Dermira, Inc.; Luke Peteson, UCB BioSciences, Inc.; Catherine Arendt, UCB, Inc.; Arthur Kavanaugh, University of California
Le texte complet de cet article est disponible en PDF. Commercial support: Dermira, Inc. Dermira and UCB are in a strategic collaboration to evaluate the efficacy and safety of certolizumab pegol in the treatment of moderate-to-severe plaque psoriasis. Medical writing support provided by Prescott Med. |
Vol 79 - N° 3S1
P. AB19 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?